Comparison of Hospital Length of Stay and Supportive Care Utilization Between Patients Treated with CPX-351 and 7+3 for Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.

Kwanza PriceZhun CaoCraig LipkinDeb Profant Scott B Robinson

Published in: ClinicoEconomics and outcomes research : CEOR (2022)

CPX-351 was associated with a shorter inpatient LOS than 7+3. Supportive care use, including blood products and anti-infectives, was similar for CPX-351 and 7+3. These findings suggest CPX-351 conveys resource advantages over 7+3 in patients with newly diagnosed t-AML and AML-MRC.

Keyphrases

acute myeloid leukemia
palliative care
healthcare
allogeneic hematopoietic stem cell transplantation
newly diagnosed
quality improvement
mental health
affordable care act
acute lymphoblastic leukemia
drug induced
electronic health record
smoking cessation